Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Alzheimer Disease Challenge Model: 24-Hour Sleep Deprivation in Healthy Volunteers, Impact on Working Memory, and Reversal Effect of Pharmacological Intervention: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
Chan Kwong A, Cassé-Perrot C, Costes-Salon MC, Jouve E, Lanteaume L, Audebert C, Rouby F, Lefebvre MN, Ranjeva JP, Beck A, Deplanque D, Ponchel A, Vervueren C, Truillet R, Babilon C, Auffret A, Richardson JC, Payoux P, Bartrés-Faz D, Blin O, Bordet R, Micallef J; Pharmacog Consortium. Chan Kwong A, et al. Among authors: auffret a. J Clin Psychopharmacol. 2020 May/Jun;40(3):222-230. doi: 10.1097/JCP.0000000000001199. J Clin Psychopharmacol. 2020. PMID: 32332458 Clinical Trial.
Neurobehavioral and Cognitive Changes Induced by Hypoxia in Healthy Volunteers.
Lanteaume L, Cassé-Perrot C, Lefebvre MN, Audebert C, Deguil J, Auffret A, Otten L, Bartrés-Faz D, Blin O, Bordet R, Micallef J. Lanteaume L, et al. Among authors: auffret a. CNS Neurol Disord Drug Targets. 2016;15(7):816-22. doi: 10.2174/1871527315666160518125612. CNS Neurol Disord Drug Targets. 2016. PMID: 26825090 Review.
Translational Challenge Models in Support of Efficacy Studies: Neurobehavioral and Cognitive Changes Induced by Transcranial Magnetic Stimulation in Healthy Volunteers.
Martin-Trias P, Bragulat V, Peña-Gómez C, Sala-Llonch R, Lanteaume L, Cassé-Perrot C, Blin O, Micallef J, Auffret A, Bartrés-Faz D. Martin-Trias P, et al. Among authors: auffret a. CNS Neurol Disord Drug Targets. 2016;15(7):802-15. doi: 10.2174/1871527315666160518124316. CNS Neurol Disord Drug Targets. 2016. PMID: 27189466 Review.
Conclusive Article: Sorting the Good from the Bad: The Different Approaches to Predict Cognitive Properties of New Symptomatic Drug Candidates for Neurodegenerative Diseases in Early Development.
Deguil J, Auffret A, Schenker E, Aujard F, Lamberty Y, Bartrès-Faz D, Herrero MT, Blin O, Micallef J, Richardson JC, Bordet R. Deguil J, et al. Among authors: auffret a. CNS Neurol Disord Drug Targets. 2016;15(7):837-8. doi: 10.2174/187152731507160808203445. CNS Neurol Disord Drug Targets. 2016. PMID: 27549168 Review. No abstract available.
Evaluation of symptomatic drug effects in Alzheimer's disease: strategies for prediction of efficacy in humans.
Deguil J, Ravasi L, Auffret A, Babiloni C, Bartres Faz D, Bragulat V, Cassé-Perrot C, Colavito V, Herrero Ezquerro MT, Lamberty Y, Lanteaume L, Pemberton D, Pifferi F, Richardson JC, Schenker E, Blin O, Tarragon E, Bordet R. Deguil J, et al. Among authors: auffret a. Drug Discov Today Technol. 2013 Sep;10(3):e329-42. doi: 10.1016/j.ddtec.2013.03.003. Drug Discov Today Technol. 2013. PMID: 24179995 Review.
73 results